TORONTO, Nov. 10 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.
("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused
biopharmaceutical company developing therapeutics for disease indications
with large markets, today announced its financial results for the quarter
ended September 30, 2008.
Selected Highlights
-------------------
During the first quarter of fiscal 2009 and up to the date of this press release, the Company achieved the following significant milestones:
ELND005 (AZD-103) - Alzheimer's Disease:
- On October 20, 2008, Elan and Transition announced the achievement of
the patient enrollment target for a Phase II clinical study of
ELND005 (AZD-103) in patients with Alzheimer's disease. The study is
a randomized, double-blind, placebo-controlled, dose-ranging, safety
and efficacy study in patients with mild to moderate Alzheimer's
disease. Each patient's planned treatment period is approximately 18
months;
TT-223 - Diabetes:
- On September 11, 2008, Transition dosed the first patient in a Phase
II clinical study of gastrin analogue, TT-223, in patients with type
2 diabetes. The study is a randomized, double-blind, placebo-
controlled, dose-ranging study to evaluate the safety, tolerability
and efficacy of daily TT-223 treatments for 12 weeks with a 6-month
follow-up. Approximately 80 patients with type 2 diabetes are
expected to be enrolled in the study and will receive a daily
treatment of TT-223 in addition to their current regimen of oral
glucose lowering agents (metformin and/or thiazolidinediones);
Drug Discovery Initiatives:
- On August 18, 2008, the Company announced the acquisition of certain
assets and the exclusive rights to selected drug discovery projects
from Forbes Medi-Tech (Re
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved |